NCT00994877

Brief Summary

Methods: The study is an observational prospective trial that includes 150 patients 18 or older admitted to our icu because of severe sepsis or septic shock as defined by the American College of Chest Physicians/ Society of Critical Care Medicine consensus conference. Patients whose primary reason for hospital admission is sepsis or patients developing sepsis after elective invasive procedure will be included. Only patients with known former primary coagulation/hypercoagulability disorder wil be excluded. Procedure: Within 12 hours of admission to the intensive care unit (ICU) blood will be drawn for the following: Blood count, glucose, urea, creatinine, liver function tests, prothrombin time, partial thromboplastin time, Ddimer, fibrinogen and TEG (thromboelastography) assay will be performed. These blood tests will be also drawn on day 2 and 4 of admission. On day one, another 3 cc of blood will be drawn and frozen in -80 degrees for levels of coagulation factors: I, II, V, VII, VIII, IX, X, XI, XII, XIII, Antithrombin III, protein C, S. Demographic data will be collected according to patient chart, and the acute physiologic and chronic health evaluation (APACHE) II score will be assessed after 24 hours. Vital signs will be collected from monitors. Informed consent will be waved due to lack of any intervention and the general condition of patients unable to sign an informed consent. Control group will include 10 healthy individuals. End point: The primary end point is to determine the common hypercoagulable/coagulation disorders according to TEG. The secondary end point is to determine whether TEG results have prognostic implications on this group of severe septic patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2009

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2009

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

September 24, 2009

Completed
20 days until next milestone

First Posted

Study publicly available on registry

October 14, 2009

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

October 14, 2009

Status Verified

October 1, 2009

Enrollment Period

1.2 years

First QC Date

September 24, 2009

Last Update Submit

October 13, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • To determine the common hypercoagulable/ coagulation disorders according to thromboelastography (TEG)

    In hospital

Secondary Outcomes (1)

  • To determine whether TEG results have prognostic implications on this group of severe septic patients

    28 day

Study Arms (2)

Septic Patients

Healthy Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients With sepsis or septic shock admitted to ICU

You may qualify if:

  • All patients age 18 years or older admitted to ICU whose primary reason for admission was sepsis or suffering sepsis or septic shock after elective surgical procedure

You may not qualify if:

  • Patients suffering primary disease affecting the coagulation system

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asaf Harofeh Medical Center

Beer Yaakov, Israel

RECRUITING

Related Publications (1)

  • Martini WZ, Cortez DS, Dubick MA, Park MS, Holcomb JB. Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma. 2008 Sep;65(3):535-43. doi: 10.1097/TA.0b013e31818379a6.

    PMID: 18784565BACKGROUND

MeSH Terms

Conditions

Shock, SurgicalSystemic Inflammatory Response Syndrome

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsShockInflammation

Study Officials

  • asaf miller, md

    Asaf Harofeh Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

September 24, 2009

First Posted

October 14, 2009

Study Start

March 1, 2009

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

October 14, 2009

Record last verified: 2009-10

Locations